Slicc* classification criteria for systemic lupus erythematosus (2012)

These revised criteria are intended to be more clinically relevant and to incorporate new immunologic information. They have not been tested for the purposes of SLE diagnosis.

Adapted from Petri M et al. Arthritis Rheum 2012;64:2677.

SLNB, sentinel lymph node biopsy; CBC, complete blood count; LFTs, liver function tests; LDH, lactate dehydrogenase; CXR, chest x-ray; CT, computed tomography; CT/PET, computed tomography/positron emission tomography; MRI, magnetic resonance imaging.

Drug Eruption Chart (blank template). This is a helpful working template for organizing all of the available patient information into one document for a patient with a suspected adverse cutaneous drug reaction (ACDR). Step 1: Compile all of the recently consumed or administered drugs (including prescription, over-the-counter, and supplements) into the chart. Step 2: Review and list the pertinent laboratory information and physical findings at the bottom of the chart. Step 3: Referring to Figure 17.1, exclude a SCAR and categorize the type of ACDR. Step 4: Based upon time intervals (see Table 17.3) and the most and least likely drugs to cause ACDR (see Table 17.2), begin to formulate the most likely culprit drugs and recommend their discontinuation. In addition, discontinue unnecessary drugs. Step 5: Longitudinal evaluation of the patient is necessary to: 1) exclude progression to a SCAR; 2) determine the response upon discontinuation of the culprit drug (noting that it might ‘get worse before it gets better’); and 3) to provide supportive care to the patient. SC, subcutaneous; WBC, white blood cell count; AST, aspartate aminotransferase; ALT, alanine aminotransferase.